Search results
AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales
Investor's Business Daily· 4 days agoFears that Humira biosimilars will erode AbbVie's top line are overblown, an analyst said Monday as...
Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
Pharmaceutical Technology via Yahoo Finance· 7 days agoAdditionally, during Q1 2024, Merck & Co finalised the acquisition of Harpoon Therapeutics, a...
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Motley Fool via Yahoo Finance· 7 days agoBy almost any measure, AbbVie (NYSE: ABBV) shares should have risen Friday. The pharmaceutical giant...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
NBC San Diego· 2 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 3 days agoAbbVie (NYSE:ABBV – Free Report) had its price objective cut by BMO Capital Markets from $195.00 to $180.00 in a report published on Monday morning, Benzinga reports. A number ...
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 7 days agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q1 2024 Earnings Call Apr 26, 2024, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks· 2 days agoFree Report) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 1.9% over this ...
AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That
Investor's Business Daily· 7 days agoAbbVie is "firing on all cylinders," an analyst said Friday after the pharma giant beat Wall...
AbbVie's newer drugs are offsetting losses of the world's once best-selling medication
Quartz· 7 days agoSales of the pharma giant's newer drugs are offsetting its Humira losses.
BMO cuts Abbvie stock PT on lower revenue outlook for Vraylar, Humira concerns By Investing.com
Investing.com· 4 days agoOn Monday, BMO (TSX:BMO) Capital Markets adjusted its outlook onAbbvie (NYSE:ABBV), a...